Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Atezolizumab Fails to Improve Survival Outcomes After Definitive Local Therapy in High-Risk HNSCC

April 8th 2024

Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.

Dr Wong on Atezolizumab After Definitive Local Therapy in High-Risk HNSCC

April 8th 2024

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Dr Villa on the Incidence of Oral Toxicities in Patients With Head and Neck Cancer

March 27th 2024

Alessandro Villa, DDS, PhD, MPH, discusses the incidence of oral toxicities in patients with head and neck cancer.

Dr Lee on Head and Neck Cancer Updates from the 2024 ACRO Summit

March 21st 2024

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN

March 20th 2024

NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

FDA Grants Fast Track Designation to MVR-T3011 for Pretreated Recurrent/Metastatic HNSCC

March 19th 2024

The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Quad Shot Radiation Plus Immunotherapy Improves Local Control in Advanced Head and Neck Cancer

March 16th 2024

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

APG-115 Produces Encouraging Disease Control in p53 Wild-Type Salivary Gland Cancer

March 12th 2024

A high rate of disease control was seen with the novel MDM2 inhibitor APG-115-alrizomadlin in patients with p53 wild-type salivary gland cancer.

Iopofosine Plus EBRT Produces Remissions, Proves Safe in Recurrent/Metastatic Head and Neck Cancer

March 5th 2024

Iopofosine plus EBRT elicited a 64% CR rate and was well tolerated in patients with locoregionally recurrent/metastatic head and neck cancer.

Frontline Lenvatinib Plus Pembrolizumab Generates Responses But Fails to Produce OS Benefit in HNSCC

March 5th 2024

Adding lenvatinib to pembrolizumab improved ORR and PFS, but not OS, vs placebo for patients with head and neck squamous cell carcinoma.

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023

The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.

Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

November 22nd 2023

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.

NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

November 13th 2023

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.

PDS0101-Based Triplet Provides Survival Benefit in HPV16+ Cancers

November 9th 2023

The combination of PDS0101, PDS0301 (formerly M-9241), and bintrafusp alfa, an investigational immune checkpoint inhibitor extended survival in patients with advanced human papillomavirus 16–positive cancers, according to final data from a phase 2 trial (NCT04287868) led by the National Cancer Institute.

Dr Hadoux on the Efficacy of Selpercatinib in RET-Mutant Medullary Thyroid Cancer

October 27th 2023

Julien Hadoux, MD, PhD, discusses the efficacy of selpercatinib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 trial.

FDA Approves Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma

October 27th 2023

The FDA has approved toripalimab-tpzi (Loqtorzi) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adult patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy.

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21st 2023

Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.

Sacituzumab Govitecan Demonstrates Modest Activity in Pretreated HNSCC

October 21st 2023

Sacituzumab govitecan-hziy led to modest but durable antitumor activity with predominant gastrointestinal toxicities in patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.